HireRight Appoints Lars Ewe as Chief Technology Officer
'Lars' extensive background in data science, artificial intelligence, automation, and analytics makes him an excellent choice to lead the many technological initiatives that are in the company's pipeline,' said Euan Menzies, President and CEO of HireRight.
Mr. Ewe will oversee the continued evolution of HireRight's global technology teams while incorporating his strong background in product strategy, architecture guidance, technology selection, and hands-on operational leadership. Prior to joining HireRight, Mr. Ewe served as the CTO at DTN, where he set the strategic direction for the innovation, data science, and technology behind the company's expansive product line. He has previously held executive leadership positions at Anaconda, Evariant, and Click Security. He earned a degree in mechanical engineering from Technical University in Munich, Germany.
'HireRight is committed to evolving the technological footprint of the background screening industry through continuous product improvements and the introduction of artificial intelligence and machine learning into their comprehensive screening processes,' said Ewe. 'I am excited to join this fantastic team and be a part of the exciting technological innovation and growth happening at the company.'
'Lars' extensive background in data science, artificial intelligence, automation, and analytics makes him an excellent choice to lead the many technological initiatives that are in the company's pipeline,' said Euan Menzies, President and CEO of HireRight. 'With his leadership, I am confident we will continue to drive innovation as we work to provide the best possible screening experience for our customers.'
About HireRight
HireRight is a leading global provider of technology-driven workforce risk management and compliance solutions. We provide comprehensive background screening, verification, identification, monitoring, and drug and health screening services for approximately 34,000 customers across the globe. We offer our services via a global platform that tightly integrates into our customers' human capital management systems, enabling highly effective and efficient workflows for workforce hiring, onboarding, and monitoring. In 2024, we screened over 60 million job applicants, employees, and contractors for our customers and processed over 120 million screens. For more information, visit www.HireRight.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
A.forall Announces the Direct Commercialization of Sodium Acetate Injection 2mEq/mL
WHITE BEAR LAKE, Minn.--(BUSINESS WIRE)--Through its U.S. subsidiary, Milla Pharmaceuticals Inc., announced the direct commercialization and launch of Sodium Acetate Injection 2mEq/mL in 20mL, 50mL, and 100mL vials. Milla Pharmaceuticals Inc. announced the direct commercialization and launch of Sodium Acetate Injection 2mEq/mL in 20mL, 50mL, and 100mL vials. Share Sodium Acetate Injection, USP is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. 'We continue supplying Sodium Acetate in the U.S. throughout this time of shortage as we have been doing over the last four years, but we are now proudly addressing the shortage directly. Thanks to our own commercial organization, we are now able to provide U.S. patients with the medicines they need most in an even more efficient way. 'This important milestone represents the company's continued investment in and increasing internal dedication to serving the U.S. marketplace, especially for products which have been or continue to be reported in shortage,' commented Erik Lazarich, President of U.S. Operations. Please see link for Full Prescribing Information. About & Milla Pharmaceuticals At our mission is all about Making Affordable Medicines Available To All: we develop value-added generic pharmaceuticals, solve product shortages and fill unmet medical needs so that patients can continue their treatment. At the same time, we are reducing costs to the healthcare system and increasing customer convenience for a more sustainable world. Milla Pharmaceuticals Inc., the U.S. subsidiary of is engaged in the development, licensing, acquisition, and commercialization of generic prescription drugs for the U.S. market, focusing on niche injectable and solution products for hospitals and clinics.
Business Wire
2 hours ago
- Business Wire
Two-Decade Innovation Journey of MagneRide ® Magneto‑Rheological Dampers
MUNICH--(BUSINESS WIRE)--When BWI Group invented and launched the MagneRide ® magneto‑rheological damper in 2002, the company has propelled MagneRide ® on an extraordinary voyage of technical innovation—an adventure of innovation, challenge and bold breakthroughs. Every generation of MagneRide ® embodies BWI Group's relentless pursuit of sharper vehicle dynamics and superior ride comfort. Constant innovation drives the company to perfect its craft, ensuring that each new iteration delivers a palpably better driving experience. MagneRide ® has elevated vehicle handling and comfort while widening its reach from exotic super‑cars and premium nameplates to a far broader market. First Generation: Started from laboratory magic The story begins in a laboratory brimming with curiosity and ambition. In 2002 the first‑generation MagneRide damper was mass produced for the very first time, endowing the debut application—the Cadillac STS—with unprecedented handling prowess. Second Generation: Reinforced system favoured by super‑cars The second‑generation MagneRide ® damper entered the market in 2006. Upgraded magneto‑rheological fluid and a newly designed piston armed the system for both enhanced comfort and assured control in varied conditions. Europe's top super‑car marques soon extended olive branches, validating MagneRide's unparalleled competitiveness in the high‑performance arena. Third Generation: Leap with speed & passion In 2011, the third‑generation MagneRide ® damper's evolution came with dual‑coil technology pushing response frequency to 1,000 adjustments per second. Meanwhile, dual‑layer sealing made the system more durable, and slashed maintenance costs. Fourth Generation: Benchmark in smart‑drive era Arriving in 2020, the latest generation of MagneRide ® suspension system once again stunned the industry and raised the bar for future mobility. Thanks to a cutting‑edge ECU, wheel‑end accelerometers and an IMU, magneto‑rheological fluid reacts in a lightning‑quick 0.5 millisecond. BWI Group's proprietary algorithmic refinements significantly enhance vehicle stability, ushering in a brand‑new driving paradigm. The latest MagneRide ® suspension system endures more than 300,000 km of gruelling service and operates flawlessly in extremes ranging from −30 °C to 105 °C. It conquers every environment beyond the laboratory, and many flagship models have adopted the system. The fourth generation MagneRide ® suspension system paves the way for boundless possibilities in automotive innovation. From the inaugural invention, through the benchmark‑setting fourth generation, every stride attests to BWI Group's tireless quest for technical excellence and precise understanding of market needs.
Business Wire
3 hours ago
- Business Wire
NIQ Announces Pricing of Initial Public Offering
CHICAGO--(BUSINESS WIRE)--NIQ Global Intelligence plc (the 'Company') announced today the pricing of its initial public offering of 50,000,000 of its ordinary shares at a public offering price of $21.00 per ordinary share. The underwriters will have a 30-day option to purchase up to an additional 7,500,000 ordinary shares from the selling shareholder at the initial public offering price less underwriting discounts and commissions. The Company's ordinary shares are expected to begin trading on the New York Stock Exchange on July 23, 2025, under the ticker symbol 'NIQ.' The offering is expected to close on July 24, 2025, subject to customary closing conditions. The Company intends to use the net proceeds that it receives from the offering, together with available cash, as necessary, to repay amounts outstanding under its revolving credit facility and a portion of the amounts outstanding under its US term loan facility and to use any remaining net proceeds for working capital and for general corporate purposes. The Company will not receive any proceeds from the sale of ordinary shares by the selling shareholder. J.P. Morgan, BofA Securities, UBS Investment Bank, Barclays and RBC Capital Markets are acting as joint lead book-running managers for the offering. Citigroup, Wells Fargo Securities, BNP Paribas, Deutsche Bank Securities, BMO Capital Markets and KKR are also acting as joint book-running managers. Baird, Needham & Company, Stifel, William Blair, Capital One Securities, Fifth Third Securities, SMBC Nikko, Academy Securities, Loop Capital Markets and Roberts & Ryan are acting as co-managers for the offering. This offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering, when available, may be obtained from: J.P. Morgan Securities LLC, Attention: c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or email: prospectus-eq_fi@ and postsalemanualrequests@ BofA Securities, Inc., NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, Attention: Prospectus Department, by email: or UBS Securities LLC, 1285 6th Ave, New York, NY 10019, by telephone: (888) 827-7275. A registration statement on Form S-1 relating to the offering was declared effective by the Securities and Exchange Commission on July 22, 2025. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About NIQ NIQ is a leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. NIQ combined with GfK in 2023, bringing together two industry leaders with unparalleled global reach. Our global reach spans over 90 countries covering approximately 85% of the world's population and more than $ 7.2 trillion in global consumer spend. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full View™. NIQ-IR
